Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC
Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.
Delvys Rodriguez-Abreu, MD, medical oncologist at Hospital Universitario Insular de Gran Canaria in Gran Canaria, Spain, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non—small cell lung cancer (NSCLC).
In the phase 3 trial, the median time from randomization to data cutoff was 31.0 months, Rodriguez-Abreu says. Patients were randomized 2:1 to receive 35 cycles of pembrolizumab (Keytruda) at 200 mg every 3 weeks or placebo every 3 weeks plus 4 cycles of pemetrexed and carboplatin/cisplatin followed by maintenance pembrolizumab. Of the 616 patients with NSCLC enrolled on the study, 410 received pembrolizumab plus chemotherapy and 206 patients received placebo plus chemotherapy.
At the time of the data cutoff, which was May 20, 2019, 17 patients in the pembrolizumab-plus-chemotherapy arm were still receiving initially assigned treatment compared with only 1 patient in the placebo-plus-chemotherapy arm. A total of 84 patients, concludes Rodriguez-Abreu.
